SELECT ISSUE
HIGHLIGHTS
Plagiarism’s meaning comes from the Latin word ‘plagiarius,’ which means to kidnap. When someone uses the work of another writer or artist without properly citing the source or giving credit, that’s plagiarism. [...]
Committe on Publication Ethics
A forum for responsible and ethical research publishing – Code of Conduct and Best Practice Guidelines for Journal Editors.
Members Area
The Consumption of Alanerv® Nutritional Supplement and the Dynamic of Some Inflammatory Markers in Post-Acute Stroke Patients Undergoing Rehabilitation
Delia CINTEZA, Mihai BERTEANU, Suzana VLADOIU, Bogdan Nicolae MANOLESCU and Horatiu DINU
ABSTRACT
Objectives: Stroke is followed by an inflammatory response lasting up to several months. Moreover, many of the stroke-related comorbidities (i.e., diabetes mellitus, dyslipidemia, cardiovascular disease, and atherosclerosis) are characterized by an pro-inflammatory status.
Material and Methods: We designed this pilot study to evaluate the relation between the consumption of a nutritional supplement (ALAnerv®) and the dynamic of the inflammatory status in post-acute stroke patients undergoing rehabilitation. The study population comprised 28 patients which were assigned into two study groups, named (-) ALA and (+) ALA. All subjects followed the same rehabilitation program. There were no significant differences in respect to the standard medication between the groups. Moreover, patients from the (+) ALA group received ALAnerv® for two weeks (2 pills/day). We assessed IL-1α, IL-6, TNF-α, sICAM-1, and myeloperoxidase in blood samples taken at the beginning and at the end of the study period.
Outcomes: In the (+) ALA group only IL-1α (- 9.9% ± 3.7, P = 0.013) and IL-6 (- 26.5% ± 8.2, P = 0.003) significantly decreased during the study period. The multiple regression analysis indicated that the ALAnerv® treatment was responsible for the significant decrease of IL-6 level (P = 0.008). Moreover, the percentage of IL-6 variation between the study groups reached statistical significance (8.4% ± 11.5 vs. – 26.5% ± 8.2, P = 0.034).
Conclusions: These results indicate that ALAnerv® could be beneficial for the correction of the inflammatory status in post-acute stroke patients and underline the need of a longer treatment period with a higher dose.
Keywords: blood pressure variability, ventricular dysfunction, diabetes, hypertension